Healthcare Industry News: Mylan
News Release - October 1, 2007
Mylan Announces Appointment of Brian Byala as Senior Vice President and TreasurerPITTSBURGH, Oct. 1 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced the appointment of Brian Byala as Senior Vice President and Treasurer, effective October 22, 2007. Mr. Byala joins Mylan from Pfizer Inc. where he was Assistant Treasurer with responsibility for treasury planning in both New York and Dublin. Mr. Byala spent more than 10 years at Pfizer in various treasury positions of increasing responsibility. Prior to Pfizer, Mr. Byala was employed by Grant Thornton in Durban, South Africa.
Mr. Byala has extensive experience with the management of both short- and long-term debt issuance, financial asset investment, stock repurchase programs, foreign exchange risk, FAS 133 hedge accounting, capital structure analysis and daily treasury operations. His responsibilities have also included Sarbanes-Oxley compliance and serving as the treasury lead during large scale corporate integrations.
Mylan Vice Chairman and CEO Robert J. Coury commented: "As we expand our footprint and operations around the world, it is more important than ever that we maintain an optimal capital structure that balances Mylan's strategic goals, shareholder value creation, and dynamic market conditions. Brian's extensive knowledge and experience managing capital structures of large multi- national companies will ensure that we maintain a best-in-class treasury function at Mylan that meets the needs of our evolving business. As I've stated many times, we are clearly focused on building up our management team with the best and brightest talent in the industry. I'm very pleased to welcome Brian to the Mylan family."
Mr. Byala earned an MBA from the Johnson Graduate School of Management at Cornell University, a graduate diploma in taxation and a bachelor's of commerce (honors) from the University of Natal-Durban in South Africa.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products. For more information about Mylan, please visit http://www.Mylan.com .
Source: Mylan Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.